Amgen Q3 revenue up 12% to $9.6B, GAAP EPS $5.93, non-GAAP EPS $5.64

AMGEN INC

2025-Q3 EPS reported $11.77 revenue$26,885,000,000

Revenue $9.6B (+12% YoY), product sales growth 12% on 14% volume growth, partially offset by 4% lower net price.
GAAP EPS $5.93 (+14% YoY), includes $400M Otezla intangible asset impairment charge.
Non-GAAP EPS $5.64 (+1% YoY); non-GAAP operating margin 47.1%, down 2.5 ppt.
Free cash flow $4.2B vs $3.3B in Q3 2024, driven by working capital timing and lower interest.
Sixteen products delivered double-digit sales growth including Repatha, EVENITY, TEZSPIRE, and BLINCYTO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.